Comparison of Analgesic Effect of Volatile Anesthetics
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02830243|
Recruitment Status : Recruiting
First Posted : July 12, 2016
Last Update Posted : July 12, 2016
|Condition or disease||Intervention/treatment||Phase|
|Anesthesia||Drug: Sevoflurane Drug: Desflurane||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||90 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Investigator, Outcomes Assessor)|
|Official Title:||The Comparison of Analgesic Effect of Volatile Anesthetics Using Surgical Pleth Index|
|Study Start Date :||July 2016|
|Estimated Primary Completion Date :||June 2018|
|Estimated Study Completion Date :||June 2018|
Anesthesia was maintained with sevoflurane.
End-tidal concentration of sevoflurane was maintained at age-corrected 1 minimum alveolar concentration throughout the study period. The remifentanil infusion rate was adjusted using TCI pump to achieve surgical pleth index between 20 and 50.
Other Name: SEVO
Anesthesia was maintained with desflurane.
End-tidal concentration of desflurane was maintained at age-corrected 1 minimum alveolar concentration throughout the study period. The remifentanil infusion rate was adjusted using TCI pump to achieve surgical pleth index between 20 and 50.
Other Name: DES
- Remifentanil consumption (µg/kg/min) [ Time Frame: During the intraoperative period ]
- Target effective site concentration of remifentanil (ng/ml) [ Time Frame: After at least 10 min of stable surgical pleth index values ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02830243
|Contact: Kyoungho Ryu, M.D.||+email@example.com|
|Korea, Republic of|
|Kangbuk Samsung Hospital||Recruiting|
|Seoul, Korea, Republic of, 03181|
|Contact: Kyoungho Ryu, M.D. +82-2-2001-1376 firstname.lastname@example.org|
|Principal Investigator:||Kyoungho Ryu, M.D.||Kangbuk Samsung Hospital|